- Entheon Biomedical is proceeding on a non-brokered private placement financing for gross proceeds of up to $3 million
- Entheon will issue up to 30,000,000 Units at a price of $0.10 per unit
- Proceeds will be used for research and development activities and general working capital
- Entheon is a biotechnology research and development company
- Entheon Biomedical Corp. (ENBI) opened trading at C$0.125 per share
Entheon Biomedical (ENBI) is proceeding on a non-brokered private placement financing for gross proceeds of up to $3 million.
Entheon will issue up to 30,000,000 units at a price of $0.10 per unit. Each unit will consist of one common share and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share at an exercise price of $0.15 per share in year one and $0.25 in years two and three.
Proceeds will be used for research and development activities and general working capital and corporate purposes.
All securities issued will be subject to a four-month hold period.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N, N-dimethyltryptamine-based psychedelic therapeutic products to treat addiction and substance use disorders.
Entheon Biomedical Corp. (ENBI) opened trading at C$0.125 per share.
